BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE. BioCryst began shipping ORLADEYO oral pellets for pediatric patients during the week of the call. Gayer said BioCryst continued to add slightly more than its historical average of about 60 new prescribing physicians per month. 2026 ORLADEYO revenue guidance: Maintained at $625 million to $645 million. Ghias said BioCryst intends to pursue external business-development opportunities focused on high-value, clinically validated assets, particularly early- to mid-stage programs.